Nonribosomal antibacterial peptides that target multidrug-resistant bacteria

Abstract

This review summarizes the development of nonribosomal antibacterial peptides from untapped sources that target multidrug-resistant bacteria.

Anti‐Infective Application of Graphene‐Like Silicon Nanosheets via Membrane Destruction

“…To date, various advanced biomaterials with antimicrobial properties have been developed based on either contact killing by bactericidal polymers, or the release of biocides bound to the biomaterials . Bactericidal polymers such as polycations derived from quaternary ammonium compounds and polyethylenimine derivatives are commonly used owing to their potent antibacterial activity via membrane integrity disruption or membrane lysis mechanism . However, their practical applications are hindered by their potential cytotoxicity, which often causes inflammation and irritation.…”

Tridecaptin-inspired antimicrobial peptides with activity against multidrug-resistant Gram-negative bacteria

“…At this stage the triple Oct-TriA 2 mutant 8 showed no antimicrobial activity at the highest concentrations tested (100 μg mL −1 ). Gratifyingly, Oct-TriA 2 (2,8-D-Orn, 7-Orn) (7) showed comparable activity to Oct-TriA 1 against the A. baumannii strains and four-fold enhanced activity against P. pseudoalcaligenes, although was two-to four-fold less active against the K. pneumoniae strains.…”

“…In recent years many NRPs have been discovered (or re-elucidated) that kill MDR bacteria, often through novel mechanisms of action. 6,7 The tridecaptins are a family of linear NRPs that are N-terminally acylated and composed of 13 amino acids, more than half of which are non-proteinogenic residues (Fig. 1).…”

Anti-HIV agent azidothymidine decreases Tet(X)-mediated bacterial resistance to tigecycline in Escherichia coli

“…Accordingly, development of novel antibiotic candidates is the most straightforward approach to address this issue 11,12 . However, recent investigations implied that this approach is not so costeffective due to the huge time and financial investment 13 .…”

“…Consistently, there are only several novel antibiotics such as daptomycin 15 were approved by FDA in the past decades. Conceivably, it is more and more difficult to mine novel lead compounds by traditional screening platform 11 . In contrast, screening potential antibiotic adjuvants from FDA-approved compounds offers a promising strategy to repurpose our existing antibiotic and overcome resistant bacteria 13,16 .…”